
Opinion|Videos|July 22, 2024
Recent Data on Bimekizumab for Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Bimekizumab is a biologic under investigation for hidradenitis suppurativa (HS). What did recent phase 3 results demonstrate?
Advertisement
Related to this article

In a single-clinic study, 61.5% of patients with psoriasis screened positive for psoriatic arthritis using a validated questionnaire.

San Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy teams and dashboards.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Most Patients With Psoriasis Screened Positive for PsA at One Dermatology Clinic
3
Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty Say
4
Low CRC Incidence Found After Endoscopic Mucosal Resection
5


